05.06.2026

Bayer Expands Ophthalmology Portfolio with Acquisition of Perfuse Therapeutics in Deal Worth Up to $2.45 Billion

Key Takeaways Bayer will acquire Perfuse Therapeutics in a deal valued at up to $2.45 billion In the deal, Bayer gains full rights to PER-001, a phase 2 therapy candidate for glaucoma and diabetic retinopathy (DR) PER-001 is being studied as one of the first potential treatments designed to improve visual field outcomes in glaucoma patients and reduce ischemia in DR Bayer has entered into an agreement to acquire Perfuse Therapeutics, a clinical-stage biopharmaceutical company focused on developing therapies for ischemia-induced ocular diseases. The acquisition gives Bayer full rights to PER-001, an investigational small molecule endothelin receptor antagonist currently in phase 2 clinical development for glaucoma and diabetic retinopathy (DR).